LQDA.NASDAQLiquidia CORP

Form 4: Liquidia CBO Adair Sells Shares After RSU Vesting

Sentiment:

Insider Transaction Report


Liquidia Corp's Chief Business Officer, Jason Adair, reported the acquisition of common stock from RSU vesting and a subsequent sale to cover tax obligations.

Summary

  • Jason Adair, Chief Business Officer of Liquidia Corp (LQDA), reported transactions involving the acquisition and disposition of common stock.
  • On November 28, 2025, 1,563 Restricted Stock Units (RSUs) converted into an equal number of common shares.
  • Following this conversion, Adair's direct beneficial ownership of common stock increased to 176,561 shares.
  • On December 1, 2025, Adair sold 693 shares of common stock at a price of $32.19 per share.
  • This sale was executed pursuant to a Rule 10b5-1 plan adopted on June 13, 2022, and was specifically to cover taxes associated with the settlement of RSUs granted on January 16, 2022.
  • After the sale, Adair's direct beneficial ownership of common stock decreased to 175,868 shares.
  • Adair also holds 1,562 derivative securities in the form of Restricted Stock Units, which convert into common stock on a one-for-one basis.
  • His total beneficial ownership includes 10,937 unvested RSUs from a July 6, 2023 grant, 22,268 unvested RSUs from a January 11, 2024 grant, 61,895 unvested RSUs from a January 11, 2025 grant, and 11,586 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including RSU vesting and a tax-related sale under a 10b5-1 plan. These are standard events for executives and do not inherently indicate a positive or negative shift in company fundamentals or outlook.

Positives

  • The vesting of Restricted Stock Units represents a realization of compensation for the Chief Business Officer.
  • The transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating a structured and pre-planned approach to insider transactions.

Negatives

  • The sale of 693 shares of common stock, even for tax purposes, reduces the Chief Business Officer's direct equity ownership in the company.

Risks

  • While the sale was for tax purposes and under a 10b5-1 plan, any insider selling can sometimes be perceived negatively by the market, potentially leading to minor short-term sentiment shifts.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transaction reports (Form 4s) are routine disclosures for publicly traded companies. The reported transactions, involving RSU vesting and a tax-related sale under a 10b5-1 plan, are common occurrences for executives in the biotechnology and pharmaceutical industries, reflecting standard compensation practices and personal financial planning.

Stakeholder Impact

  • Shareholders: The sale of a relatively small number of shares by an executive, even for tax purposes, slightly dilutes the executive's direct ownership, but is unlikely to have a material impact on the company's stock price or long-term shareholder value given its routine nature and execution under a 10b5-1 plan.

Key Dates

DateDescription
01/16/2022Reporting Person was granted 25,000 Restricted Stock Units (RSUs).
06/13/2022Reporting Person adopted a Rule 10b5-1 plan for future stock transactions.
01/16/202325% of the 25,000 RSUs granted on January 16, 2022, vested.
07/06/2023Reporting Person was granted 25,000 RSUs.
01/11/2024Reporting Person was granted 39,588 RSUs.
01/11/2025Reporting Person was granted 61,895 RSUs.
11/28/20251,563 Restricted Stock Units converted into common stock.
12/01/2025693 shares of common stock were sold at $32.19 per share.
12/02/2025Date of signature for the Form 4 filing.

Recommendation

hold

This Form 4 reports routine insider transactions involving the vesting of restricted stock units and a subsequent sale of a portion of those shares to cover tax liabilities, executed under a pre-arranged 10b5-1 plan. Such transactions are common for executives and do not typically signal a change in the company's fundamental outlook or the executive's long-term commitment. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Liquidia Corp, LQDA, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Jason Adair, Chief Business Officer, 10b5-1 Plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.